ENTRADA THERAPEUTICS, INC. Increase Decrease In Operating Lease Liability
ENTRADA THERAPEUTICS, INC. (TRDA) reported Increase Decrease In Operating Lease Liability of -$2.39 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-05
- ENTRADA THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$1.21M.
- ENTRADA THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$1.18M.
- ENTRADA THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$1.47M.
- ENTRADA THERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$2.34M.
- ENTRADA THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2025 was -$8.28M.
- ENTRADA THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2024 was -$9.02M.
- ENTRADA THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2023 was -$11.86M.
- ENTRADA THERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2022 was -$7.45M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$2.39M 10-Q · filed 2026-08-05 | -$3.86M derived: sum of 3 quarters · filed 2026-08-05 | -$6.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$1.18M 10-Q · filed 2026-05-07 | -$2.65M derived: sum of 2 quarters · filed 2026-05-07 | -$4.99M derived: sum of 3 quarters · filed 2026-05-07 | -$7.25M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$3.81M derived: sum of 2 quarters · filed 2026-02-26 | -$6.07M derived: sum of 3 quarters · filed 2026-08-05 | -$8.28M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$2.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$4.60M derived: sum of 2 quarters · filed 2026-08-05 | -$6.81M 10-Q · filed 2025-11-06 | -$8.91M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$2.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$4.46M 10-Q · filed 2026-08-05 | -$6.57M derived: sum of 3 quarters · filed 2026-08-05 | -$9.70M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$2.21M 10-Q · filed 2026-05-07 | -$4.32M derived: sum of 2 quarters · filed 2026-05-07 | -$7.45M derived: sum of 3 quarters · filed 2026-05-07 | -$9.44M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$2.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$5.24M derived: sum of 2 quarters · filed 2026-02-26 | -$7.22M derived: sum of 3 quarters · filed 2026-02-26 | -$9.02M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$3.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$5.12M derived: sum of 2 quarters · filed 2025-11-06 | -$6.92M 10-Q · filed 2025-11-06 | -$6.08M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$1.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$3.79M 10-Q · filed 2025-08-06 | -$2.95M derived: sum of 3 quarters · filed 2025-08-06 | -$6.91M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$1.80M 10-Q · filed 2025-05-08 | -$957.00K derived: sum of 2 quarters · filed 2025-05-08 | -$4.92M derived: sum of 3 quarters · filed 2025-05-08 | -$11.71M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $841.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$3.12M derived: sum of 2 quarters · filed 2025-02-27 | -$9.91M derived: sum of 3 quarters · filed 2025-02-27 | -$11.86M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$3.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$10.75M derived: sum of 2 quarters · filed 2024-11-05 | -$12.70M 10-Q · filed 2024-11-05 | -$14.72M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$6.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$8.74M 10-Q · filed 2024-08-13 | -$10.76M derived: sum of 3 quarters · filed 2024-08-13 | -$12.72M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$1.95M 10-Q · filed 2024-05-07 | -$3.96M derived: sum of 2 quarters · filed 2024-05-07 | -$5.93M derived: sum of 3 quarters · filed 2024-05-07 | -$7.87M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$2.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$3.98M derived: sum of 2 quarters · filed 2024-03-13 | -$5.92M derived: sum of 3 quarters · filed 2024-03-13 | -$7.45M 10-K · filed 2024-03-13 |
| 2022-09-30 | -$1.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$3.91M derived: sum of 2 quarters · filed 2023-11-07 | -$5.44M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | -$1.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$3.47M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | -$1.53M 10-Q · filed 2023-05-10 | |||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |